Fig. 4

HSVtk/GCV therapy using the GSDMB enhancer-driven lentivirus vector improved the survival rate of PD mice. (a) A lentiviral therapeutic vector for GSDMB enhancer (Enh)-driven expression of herpes simplex virus thymidine kinase (HSVtk). (b) Cell proliferation assays on 60As6 and Met-5A transduced with the therapeutic vector, performed by incubation in the medium with (+)/without (−) ganciclovir (GCV). (c) A regimen of HSVtk/GCV therapy for PD mice. Bar, standard deviation, P, P -value of Student’s t-test between the cultured cells with (+) and without (−) GCV. (d) Microscopic observation exhibited a small population of 60As6GFP cells (green fluorescence) implanted into mouse peritoneum at day 10. (e) Number of survived mice after HSVtk/GCV therapy with the sense-strand expressing vector (red) and with an antisense-strand expressing vector as reference (blue). Mean survival time of each group is shown at the right side with P- value of Student’s t-test between the two groups